Canlyniadau Chwilio - Christopher G. Azzoli

Mireinio'r Canlyniadau
  1. 1
    Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer

    Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer gan Anna F. Farago, Christopher G. Azzoli

    Cyhoeddwyd 2017
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

    American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer gan Christopher G. Azzoli, Giuseppe Giaccone, Sarah Temin

    Cyhoeddwyd 2010
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

    2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer gan Christopher G. Azzoli, Sarah Temin, Giuseppe Giaccone

    Cyhoeddwyd 2012
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Basic Mechanisms of Therapeutic Resistance to Radiation and Chemotherapy in Lung Cancer

    Basic Mechanisms of Therapeutic Resistance to Radiation and Chemotherapy in Lung Cancer gan Henning Willers, Christopher G. Azzoli, Wil L. Santivasi, Fen Xia

    Cyhoeddwyd 2013
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors

    Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors gan Marie Brevet, Melissa L. Johnson, Christopher G. Azzoli, Marc Ladanyi

    Cyhoeddwyd 2010
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer

    Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer gan Jamie E. Chaft, Andreas Rimner, Walter Weder, Christopher G. Azzoli, Mark G. Kris, Tina Cascone

    Cyhoeddwyd 2021
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    Clinical Outcomes with Perioperative Chemotherapy in Sarcomatoid Carcinomas of the Lung

    Clinical Outcomes with Perioperative Chemotherapy in Sarcomatoid Carcinomas of the Lung gan Jamie E. Chaft, Camelia S. Sima, Michelle S. Ginsberg, James Huang, Mark G. Kris, William D. Travis, Christopher G. Azzoli

    Cyhoeddwyd 2012
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping

    Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping gan Geoffrey R. Oxnard, Vincent A. Miller, Mark E. Robson, Christopher G. Azzoli, William Pao, Marc Ladanyi, Maria E. Arcila

    Cyhoeddwyd 2012
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced, Previously Untreated, Squamous Non-small Cell Lung Cancer

    BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced, Previously Untreated, Squamou... gan John D. Hainsworth, Fang Ting Liang, Jane E. Huang, David A. Karlin, Kenneth Russell, Leonardo Faoro, Christopher G. Azzoli

    Cyhoeddwyd 2010
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Identification of a human achaete-scute homolog highly expressed in neuroendocrine tumors.

    Identification of a human achaete-scute homolog highly expressed in neuroendocrine tumors. gan Douglas W. Ball, Christopher G. Azzoli, S B Baylin, David Chi, Shijuan Dou, H. Donis-keller, Arunthathi Cumaraswamy, Michael Borges, B D Nelkin

    Cyhoeddwyd 1993
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers

    A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers gan Bob T. Li, Alexander Drilon, Melissa L. Johnson, Meier Hsu, Camelia S. Sima, C. McGinn, Hirofumi Sugita, Mark G. Kris, Christopher G. Azzoli

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma

    The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma gan Benjamin Izar, Haiyu Zhou, Rebecca S. Heist, Christopher G. Azzoli, Alona Muzikansky, Emily Scribner, Lindsay A. Bernardo, Dora Dias‐Santagata, A. John Iafrate, Michael Lanuti

    Cyhoeddwyd 2014
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib

    Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib gan Melissa L. Johnson, Greg J. Riely, Naiyer A. Rizvi, Christopher G. Azzoli, Mark G. Kris, Camelia S. Sima, Michelle S. Ginsberg, William Pao, Vincent A. Miller

    Cyhoeddwyd 2011
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  14. 14
    Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer

    Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer gan Kevin C. De Braganca, Yelena Y. Janjigian, Christopher G. Azzoli, Mark G. Kris, M. Catherine Pietanza, Craig Nolan, Antonio Omuro, Andrei I. Holodny, Andrew B. Lassman

    Cyhoeddwyd 2010
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  15. 15
    Randomized Phase 2b Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non–Small-Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-Based Therapy

    Randomized Phase 2b Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non–Small-Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-Based Therapy gan Karen Kelly, Christopher G. Azzoli, Petr Zatloukal, István Albert, Peter Jiang, David Bodkin, José Rodrigues Pereira, Erzsébet Juhász, Nicholas Iannotti, Garry Weems, Tony Koutsoukos, Jyoti D. Patel

    Cyhoeddwyd 2012
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  16. 16
    Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations

    Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations gan Yelena Y. Janjigian, Bernard J. Park, Maureen F. Zakowski, Marc Ladanyi, William Pao, Sandra P. D’Angelo, Mark G. Kris, Ronglai Shen, Junting Zheng, Christopher G. Azzoli

    Cyhoeddwyd 2010
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  17. 17
    A phase I/II study of weekly high‐dose erlotinib in previously treated patients with nonsmall cell lung cancer

    A phase I/II study of weekly high‐dose erlotinib in previously treated patients with nonsmall cell lung cancer gan Daniel T. Milton, Christopher G. Azzoli, Robert T. Heelan, Ennapadam Venkatraman, Jorge Gómez, Mark G. Kris, Lee M. Krug, William Pao, Naiyer A. Rizvi, Megan Dunne, Vincent A. Miller

    Cyhoeddwyd 2006
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  18. 18
    Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions

    Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions gan Zofia Piotrowska, Daniel B. Costa, Geoffrey R. Oxnard, Mark S. Huberman, Justin F. Gainor, Inga T. Lennes, Alona Muzikansky, Alice T. Shaw, Christopher G. Azzoli, Rebecca S. Heist, Lecia V. Sequist

    Cyhoeddwyd 2018
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  19. 19
    Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall‐cell lung cancer

    Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall‐cell lung cancer gan Daniel T. Milton, Gregory J. Riely, Christopher G. Azzoli, Jorge Gómez, Robert T. Heelan, Mark G. Kris, Lee M. Krug, William Pao, Barbara Pizzo, Naiyer A. Rizvi, Vincent A. Miller

    Cyhoeddwyd 2007
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  20. 20
    Phase I/II Trial of Weekly Intravenous 130-nm Albumin-Bound Paclitaxel As Initial Chemotherapy in Patients With Stage IV Non–Small-Cell Lung Cancer

    Phase I/II Trial of Weekly Intravenous 130-nm Albumin-Bound Paclitaxel As Initial Chemotherapy in Patients With Stage IV Non–Small-Cell Lung Cancer gan Naiyer A. Rizvi, Gregory J. Riely, Christopher G. Azzoli, Vincent A. Miller, Kenneth Ng, John J. Fiore, Gloria Chia, Martin Brower, Robert T. Heelan, Michael Hawkins, Mark G. Kris

    Cyhoeddwyd 2008
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: